You are here: Home » 2021 » April » Archives for 29th

FXCM Group Reports Monthly Execution Data

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, April 29, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC (“FXCM Group” or "FXCM"), a leading international provider of online foreign exchange trading, CFD trading and related services, today released execution data for March 2021. To view execution data including historical spreads, execution speeds and historical price improvement data click here: https://www.fxcm.com/uk/about–fxcm/execution–transparency/.

March 2021 All Instruments Highlights:*

  • 62.7% of orders executed at price1
  • 24.6% of orders executed with positive slippage2
  • 12.7% of orders executed with negative slippage3
  • Average execution speed 30 milliseconds4

Highlighted Instruments March 2021:

Instrument Active Trader
Peak
Spread5		 Active
Trader
Non–Peak
Spread5		 Active Trader
Effective
Spread6		 At Price
Orders		 Positive
Slippage		 Negative
Slippage
XAU/USD 0.4 0.4 0.4 50.7 % 34.5 % 14.8 %
SPX500 0.4 0.4 0.4 53.5 % 27.6 % 18.9 %
NAS100 1.1 1.1 1.0 41.5 % 36.9 % 21.6 %
EUR/USD 0.1 0.4 0.2 71.4 % 19.7 % 8.9 %
GBP/USD 0.4 1.0 0.5 70.2 % 20.0 % 9.8 %
AUD/USD 0.2 0.5 0.2 73.8 % 18.3 % 7.9 %

For more information and to open a live account, traders can contact an FXCM specialist 24 hours a day, 5 days a week.

*These highlights come from orders that executed through FXCM Group from 1 March 2021, to 31 March 2021. Data excludes certain types of non–direct clients.

1Percentage of executed client trades# in March 2021, which were executed at the price clients requested.
2Percentage of executed client trades# in March 2021, which were executed at a more favorable price than the price clients requested.
3Percentage of executed client trades# in March 2021, which were executed at a less favorable price than the price clients requested.
4This defines the amount of time between when we receive the order until execution. This excludes internet latency and post trade booking.
5This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 March 2021, to 31 March 2021. The data reflects average spreads made available to FXCM clients during all trading hours.
6This data is compiled forex and CFD trading data from FXCM's Active Traders for 1 March 2021, to 31 March 2021. The data reflects the spread at which trades were executed by FXCM clients during all trading hours.
#Client trades here cover stop, limit, "at market", and entry orders. Certain non–direct clients are excluded from the data. Limit and limit entry orders would only execute at the requested price or better and cannot receive negative slippage. Price improvements are subject to available liquidity.

About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

76.31% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Between 74–89% of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8226605)

A new collaboration between SNOMED International and ICH promotes seamless data exchange in support of public health

London, United Kingdom & Geneva, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) — SNOMED International and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are announcing the release of important new maps between global medical terminologies SNOMED CT and MedDRA. This collaborative effort is the first deliverable of a new agreement entered into between SNOMED International and ICH.

ICH is an international non–profit organisation which brings together regulatory authorities and pharmaceutical industry from across the globe to discuss scientific and technical aspects of pharmaceuticals and to develop ICH guidelines. Owned by ICH, MedDRA, the Medical Dictionary for Regulatory Activities, is a rich and highly specific standardised medical terminology developed by ICH to facilitate sharing of regulatory information internationally for medical products used by humans and is used for registration, documentation and safety monitoring of medical products both before and after a product has been authorised for use. SNOMED International is the not–for–profit organization that owns and maintains SNOMED CT, the world's most comprehensive clinical terminology with over 350,000 concepts ranging across diagnosis, signs and symptoms and tens of thousands of surgical, therapeutic and diagnostic procedures.

This joint effort has produced two independent maps (MedDRA to SNOMED CT and SNOMED CT to MedDRA) which have been derived from frequently used and key pharmacovigilance MedDRA terms identified from the European Medicines Agency and the UK's Medicines & Healthcare products Regulatory Agency. In addition, a set of COVID–19 related terms are also included in the first production release of the maps to capture important aspects of the pandemic.

The maps are intended to facilitate the exchange of data between regulatory databases (which use MedDRA) and healthcare databases/electronic health records (which use SNOMED CT). In one use case, key pharmacovigilance concepts coded in SNOMED CT in an electronic health record (EHR) could be converted to MedDRA for the purpose of adverse event reporting to regulatory authorities or for the purposes of epidemiological research. In the opposite direction, these same key terms coded in MedDRA representing adverse events, warnings, and other regulatory information could be converted into SNOMED CT so that the information is available in the patient's record to aid in clinical decision–making.

The two maps were created as part of a project involving SNOMED International and ICH entitled WEB–RADR 2. Funded by the Innovative Medicines Initiative (IMI), a large–scale public–private partnership between the EU and the pharmaceutical industry association, EFPIA, IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. With the creation of the maps from the WEB–RADR 2 project, both SNOMED International and ICH have committed to their ongoing use and maintenance extending past the conclusion of the project.

Mick Foy, Medicines and Healthcare products Regulatory Agency UK and Chair of the ICH MedDRA Management Committee said "This is an exciting development and an important milestone. Developing interoperability between SNOMED CT and MedDRA has been a long–standing ambition and will greatly enhance data collection for regulatory purposes and for drug safety research".

SNOMED International CEO, Don Sweete, welcomes the evolution of the organization's relationship with ICH. "It is exciting to see a long–term alliance borne from a collaborative project created to improve drug safety for patients and citizens. This agreement serves a joint commitment by two organizations dedicated to enabling health systems interoperability across regulatory and clinical continuums."

The Production version of the two maps is being made available to licensed SNOMED CT and MedDRA users on April 30, 2021 and will be based on the January 2021 version of SNOMED CT and the September 2020 version of MedDRA. It is planned that the maps will be released annually in April.

To access the maps:

Visit SNOMED International or MedDRA's Maintenance and Support Services Organization (MSSO) for map release documents, including:

  • MedDRA–SNOMED CT Mapping Conventions are available here for SNOMED CT users and here for MedDRA users.
  • Criteria for accepting requests for additions or changes to SNOMED CT to MedDRA map and MedDRA to SNOMED CT map is available here for SNOMED CT users and here for MedDRA users.
  • Map Change Request Tool (Map CR) and Map CR User Guide

For more information on these maps and resources, please contact MedDRA MSSO (mssohelp@meddra.org) or SNOMED International (info@snomed.org).

About SNOMED International:

SNOMED International is a not–for–profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.

About the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an international non–profit organisation unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines. ICH's mission is to achieve greater harmonisation worldwide to ensure that safe, effective and high quality medicines are developed, and registered and maintained in the most resource efficient manner whilst meeting high standards. MedDRA has been developed by ICH and is continuously enhanced to meet the evolving needs of regulators and industry around the world.

To learn more about the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and MedDRA, visit www.ich.org and www.meddra.org.

Attachment


GLOBENEWSWIRE (Distribution ID 8226548)

Taconic Biosciences Launches New COVID-19 Mouse Model

RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID–19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic's COVID–19 research toolkit.

In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS–CoV–2, the virus that causes COVID–19. Conversely, the new AC22 mouse is lethality–resistant, enabling therapeutic, vaccine, and post–infection symptom research.

Although various hACE2 mouse models of lethal SARS–CoV–2 infection exist, the hACE2 AC22 lethality–resistant model is important because it permits study of sublethal infection. Most humans infected with SARS–CoV–2 survive, and an animal model which replicates sublethal disease and recovery is needed. The hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.

"While vaccines bring hope of an end to the pandemic, research on COVID–19 is still needed," shared Dr. Michael Seiler, vice president of commercial models at Taconic. "There is a huge population of people who have now had the disease. We need models that also survive this disease long enough to aid in replicating that human condition. It cannot be overstated just how important this new AC22 model is in enabling that research."

Study ready cohorts of animals are available for immediate ordering.

To learn more about hACE2 mice or Taconic's Coronavirus Toolkit, please contact Taconic at 1–888–TACONIC (888–822–6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully–licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno–oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact: Kelly Owen Grover
Director of Marketing Communications
(518) 697–3824
kelly.grover@taconic.com


GLOBENEWSWIRE (Distribution ID 8225107)